{"id":52250,"date":"2022-12-21T18:02:34","date_gmt":"2022-12-21T17:02:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/"},"modified":"2022-12-21T18:02:34","modified_gmt":"2022-12-21T17:02:34","slug":"median-technologies-financial-communications-schedule-for-the-first-half-of-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/","title":{"rendered":"Median Technologies: Financial Communications Schedule for the First Half of 2023"},"content":{"rendered":"
\n

SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nMedian Technologies (ALMDT:PA) (Paris:ALMDT), announces the publication date for its 2022 results:\n<\/p>\n\n\n\n
\n

\nPublication\n<\/p>\n<\/td>\n

\n

\nDate\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2022 results\n<\/p>\n<\/td>\n

\n

\nApril 20, 2023*\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n*Distribution after the close of trading<\/i>\n<\/p>\n

\nAbout Median Technologies:<\/strong> <\/b>About Median Technologies:<\/strong> <\/b>Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy\u00ae, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.\n<\/p>\n

\nFounded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label \u201cInnovative company\u201d by the BPI and is listed on Euronext Growth market (Paris). FR0011049824\u2013 ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext\u00ae PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedian Technologies<\/b>
Emmanuelle Leygues
\n
Head of Corporate Marketing & Financial Communications
\n
+33 6 10 93 58 88
\n
emmanuelle.leygues@mediantechnologies.com<\/span><\/a>\n<\/p>\n

\nPress – ALIZE RP<\/b>
Caroline Carmagnol
\n
+33 6 64 18 99 59
\n
median@alizerp.com<\/a>\n<\/p>\n

\nInvestors – ACTIFIN<\/b>
Ghislaine Gasparetto
\n
+33 6 21 10 49 24
\n
ggasparetto@actifin.fr<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT:PA) (Paris:ALMDT), announces the publication date for its 2022 results: Publication Date 2022 results April 20, 2023* *Distribution after the close of trading About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52250","6":"format-standard","7":"category-industry"},"yoast_head":"\nMedian Technologies: Financial Communications Schedule for the First Half of 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Median Technologies: Financial Communications Schedule for the First Half of 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT:PA) (Paris:ALMDT), announces the publication date for its 2022 results: Publication Date 2022 results April 20, 2023* *Distribution after the close of trading About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-21T17:02:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221221005206\/en\/1343975\/21\/Median_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Median Technologies: Financial Communications Schedule for the First Half of 2023\",\"datePublished\":\"2022-12-21T17:02:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/\"},\"wordCount\":254,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221221005206\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/\",\"name\":\"Median Technologies: Financial Communications Schedule for the First Half of 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221221005206\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"datePublished\":\"2022-12-21T17:02:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221221005206\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221221005206\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Median Technologies: Financial Communications Schedule for the First Half of 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Median Technologies: Financial Communications Schedule for the First Half of 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/","og_locale":"en_US","og_type":"article","og_title":"Median Technologies: Financial Communications Schedule for the First Half of 2023 - Pharma Trend","og_description":"SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT:PA) (Paris:ALMDT), announces the publication date for its 2022 results: Publication Date 2022 results April 20, 2023* *Distribution after the close of trading About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-21T17:02:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221221005206\/en\/1343975\/21\/Median_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Median Technologies: Financial Communications Schedule for the First Half of 2023","datePublished":"2022-12-21T17:02:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/"},"wordCount":254,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221221005206\/en\/1343975\/21\/Median_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/","url":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/","name":"Median Technologies: Financial Communications Schedule for the First Half of 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221221005206\/en\/1343975\/21\/Median_RGB.jpg","datePublished":"2022-12-21T17:02:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221221005206\/en\/1343975\/21\/Median_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221221005206\/en\/1343975\/21\/Median_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-financial-communications-schedule-for-the-first-half-of-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Median Technologies: Financial Communications Schedule for the First Half of 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52250"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52250\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}